热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
Brilliant Violet 650™ anti-mouse CD4 Antibod
产品名称：
Brilliant Violet 650™ anti-mouse CD4 Antibod
产品类别：
抗体
产品编号：
100545
产品应用：
100545
[价格]
规格 价格 库存
125µL ￥ 2926 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 650? under optimal conditions.
Concentration
?g sizes: 0.2 mg/mL
?L sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the ?g size, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. For immunofluorescent staining using ?l sizes, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 650? excites at 405 nm and emits at 645 nm. The bandpass filter 660/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 650? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF? Purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References

(PubMed link indicates BioLegend citation)
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Valladao A, et al. 2016. J Immunol. 197(12):4541-4551. PubMed
  2. Flamar AL, et al. 2020. Immunity. 52(4):606-619.e6.. PubMed
  3. Wilden A, et al. 2022. Front Immunol. 13:991295. PubMed
  4. Moudra A, et al. 2021. J Immunol. 206:2109. PubMed
  5. Nato G, et al. 2021. Sci Rep. 11:651. PubMed
  6. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  7. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  8. Larsen SE, et al. 2021. Sci Rep. 11:9040. PubMed
  9. Liu X, et al. 2021. eLife. 0.416666666666667. PubMed
  10. Hering L, et al. 2021. Int J Mol Sci. 22:. PubMed
  11. Li Y, et al. 2020. Nat Commun. 11:2781. PubMed
  12. Chen L, et al. 2020. J Exp Med. 217:00:00. PubMed
  13. Li J, et al. 2020. Cancer Discov. . PubMed
  14. Du X, et al. 2018. Proc Natl Acad Sci U S A. 115:E11731. PubMed
  15. Kinsella S, et al. 2021. Cell Rep. 37:109789. PubMed
  16. Li J, et al. 2020. Cancer Immunol Res. 0.529166667. PubMed
  17. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  18. Klessing S, et al. 2020. Vaccines (Basel). 8:. PubMed
  19. Hossain DMS, et al. 2018. J Clin Invest. 128:644. PubMed
  20. Li J, et al. 2018. Immunity. 49:178. PubMed
  21. Shook BA, et al. 2020. Cell Stem Cell. 26(6):880-895. PubMed
  22. Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed
  23. Casulli J, et al. 2019. Nat Commun. 10:2121. PubMed
  24. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  25. Chen YG, et al. 2020. Molecular Cell. 76(1):96-109. PubMed
  26. Liu C et al. 2019. Immunity. 51(2):381-397 . PubMed
  27. Ullrich L, et al. 2021. Front Immunol. 12:729607. PubMed
  28. Sanmarco LM, et al. 2021. Nature. 590:473. PubMed
  29. Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed
  30. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  31. Wang G, et al. 2021. Cell Host Microbe. 29(5):777-791.e6. PubMed
  32. Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed
  33. Macal M et al. 2018. Immunity. 48(4):730-744 . PubMed
  34. Montalban-Arques A, et al. 2021. Cell Host Microbe. :. PubMed
  35. Asadi Shahmirzadi A, et al. 2020. Cell Metabolism. 32(3):447-456.e6. PubMed
  36. Georgiadou A, et al. 2022. Elife. 11:. PubMed
  37. Tannig P, et al. 2020. Vaccines (Basel). 8:. PubMed
  38. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  39. Scharschmidt TC, et al. 2017. Cell Host Microbe. 1.199305556. PubMed
  40. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  41. Mathur AN, et al. 2019. Immunity. 50:655. PubMed
  42. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  43. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  44. Parigger T, et al. 2021. Int J Mol Sci. 22:. PubMed
  45. Louise V Webb et al. 2019. Immunity. 50(2):348-361 . PubMed
  46. Hester AK, et al. 2022. Cell Rep. 38:110363. PubMed
RRID
AB_11126142 (BioLegend Cat. No. 100545) AB_2562529 (BioLegend Cat. No. 100555) AB_2562098 (BioLegend Cat. No. 100546)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线